Autoimmune Bullous Skin Disorders

  • Michael Hertl
  • Emmanuel Laffitte
  • Luca Borradori
  • Christian Rose
  • Detlef Zillikens
  • Mei Chen
  • Dafna Hallel-Halevy
  • Celina Nadelman
  • David T. Woodley


Pemphigus (from the Greek pemphix, meaning bubble or blister) encompasses a group of life-threatening autoimmune blistering diseases characterized by intraepithelial blister formation (Lever 1953; Huilgol et al. 1995; Hertl 2000). The molecular basis for blister formation is a loss of adhesion between keratinocytes caused by circulating autoantibodies (auto-Ab) directed against intercellular adhesion structures of epidermal keratinocytes (Amagai et al. 1991; Bedane et al. 1996). Several forms of pemphigus have been classified depending on the level of the intraepidermal split formation. In the pemphigus vulgaris (PV) group, the blisters are located just above the basal layer whereas in the pemphigus foliaceus (PF) group, the blisters occur within the upper layers of the epidermis (Bedane et al. 1996). Other members of the pemphigus group are paraneoplastic pemphigus (PNP), which generally occurs in patients with lymphoma, and drug-induced pemphigus, which usually develops after the administration of penicillamine. Based on recent immunological studies, a molecular distinction can be made by the characterization of the specificity of the auto-Ab that recognize different molecular target structures.


Human Leukocyte Antigen Class Bullous Pemphigoid Dermatitis Herpetiformis Basement Membrane Zone Pemphigus Foliaceus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ahmed AR. Blose DA (1984) Pemphirrus vegetans. Neumann type and Hallopeau type. Tnt 23: 135–141Google Scholar
  2. Ahmed AR, Yunis EJ, Khatri K (1990) Major histocompatibility complex haplotype studies in Ashkenazi Jewish patients with pemphigus vulgaris. Proc Natl Acad Sci USA 87: 7658–7662.PubMedCrossRefGoogle Scholar
  3. Ahmed AR, Wagner R, Khatri K (1991) Major histocompatibility complex haplotypes and class II genes in non-Jewish patients with pemphigus vulgaris. Proc Natl Acad Sci USA 88: 5056–5061PubMedCrossRefGoogle Scholar
  4. Ahmed AR, Mohimen A, Yunis AJ (1993) Linkage of pemphigus vulgaris antibody to the major histocompatibility complex in healthy relatives of patients. J Exp Med 177: 419–424PubMedCrossRefGoogle Scholar
  5. Amagai M, Klaus-Kovtun V, Stanley JR (1991) Auto-Ab against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell 67: 869–877PubMedCrossRefGoogle Scholar
  6. Amagai M, Karpati S, Prussick R, Klaus-Kovtun V, Stanley JR (1992) Autoantibodies against the amino-terminal cadherin-like binding domain of pemphigus vulgaris antigen are pathogenic. J Clin Invest 90: 919–926PubMedCrossRefGoogle Scholar
  7. Amagai M, Hashimoto T, Shimizu N, Nishikawa T (1994) Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg 3) produced by baculovirus: J Clin Invest 94: 59–67Google Scholar
  8. Amagai M, Nishikawa T, Shimizu N, Green KJ, Hashimoto T (1995) Antigen-specific immunoadsorption of pathogenic autoantibodies in pemphigus foliaceus. J Invest Dermatol 104: 895–901PubMedCrossRefGoogle Scholar
  9. Amagai M, Koch PJ, Nishikawa T, Stanley JR (1996) Pemphigus vulgaris antigen (desmoglein 3) is localized in the lower epidermis, the site of blister formation in patients. J Invest Dermatol 106: 351–355PubMedCrossRefGoogle Scholar
  10. Amagai M, Nishikawa T, Nousari HC, Anhalt GJ, Hashimoto T (1998) Antibodies against desmoglein 3 (pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic pemphigus and cause acantholysis in vivo in neonatal mice. J Clin Invest 102: 775–782PubMedCrossRefGoogle Scholar
  11. Amagai M, Tsunoda K, Suzuki H, Nishifuji K, Koyasu S, Nishikawa T (2000a) Use of autoantigen-knockout mice in developing an active autoimmune disease model for pemphigus. J Clin Invest. 105: 625–31PubMedCrossRefGoogle Scholar
  12. Amagai M, Matsuyoshi N, Wang ZH, Andl C, Stanley JR (2000b) Toxin in bullous impetigo and staphylococcal scalded skin syndrome targets desmoglein 1. Nature Med 6: 1275–1277PubMedCrossRefGoogle Scholar
  13. Anhalt, GJ, Labib KS, Vorhees JS, Beals TF, Diaz LA (1982) Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N Engl J Med 306: 1189–1192PubMedCrossRefGoogle Scholar
  14. Anhalt GJ, Kim S, Stanley JR (1990) Paraneoplastic pemphigus: an autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 323: 1729–1735PubMedCrossRefGoogle Scholar
  15. Bedane C, Prost C, Thomine E, Intrator L, Joly P, Caux F, Blecker M, Bernard P, Leboutet MJ, Tron F, Lauret P, Bonnetblanc JM, Dubertret L (1996) Binding of autoantibodies is not restricted to desmosomes in pemphigus vulgaris: comparison of 14 cases of pemphigus vulgaris and 10 cases of pemphigus foliaceus studied by western immunoblot and immunoelectron microscopy. Arch Dermatol Res 288: 343–352PubMedCrossRefGoogle Scholar
  16. Bhol K, Ahmed AR, Aoki V, Mohimen A, Nagarwalla N, Natarajan K (1995) Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in pemphigus vulgaris: a model for autoimmunity. Proc Natl Acad Sci U S A 92: 5239–5243PubMedCrossRefGoogle Scholar
  17. Brandsen R, Frusic-Zlotkin M, Lyubimov H, Yunes F, Michel B, Tamir A, Milner Y, Brenner S (1997) Circulating pemphigus IgG in families of patients with pemphigus: comparison of indirect immunofluorescence, direct immunofluorescence, and immunoblotting. J Am Acad Dermatol 36: 44–52PubMedCrossRefGoogle Scholar
  18. Brenner S, Bialy-Golan A, Anhalt GJ (1997) Recognition of pemphigus antigens in drug-induced pemphigus vulgaris and pemphigus foliaceus. J Am Acad Dermatol 36: 919–923PubMedCrossRefGoogle Scholar
  19. Delgado JC, Yunis EJ, Ahmed AR, Alper CA, Ahmad M Khan AA, Rehman SB, Rojas AI, Bhol K, Yunis JJ, Hameed A (1997) Pemphigus vulgaris autoantibody response is linked to HLA-DQB1*0503 in Pakistani patients. Hum Immunol 57: 110–119PubMedCrossRefGoogle Scholar
  20. Ding X, Fairley JA, Diaz LA, Lopez-Swiderski A, Mascaro JM Jr, Aoki V (1997). Mucosal and mucocutaneous (generalized) pemphigus vulgaris show distinct autoantibody profiles. J Invest Dermatol 109: 592–596PubMedCrossRefGoogle Scholar
  21. Emery DJ, Diaz LA, Fairly JA, Lopez A, Taylor AF, Giudice GJ (1995) Pemphigus foliaceus and pemphigus vulgaris autoantibodies react with the extracellular domain of desmoglein 1. J Invest Dermatol 104: 323–328PubMedCrossRefGoogle Scholar
  22. Esaki C, Kitajima Y, Osada K, Yamada T, Seishima M (1995) Pharmacologic evidence for involvement of phospholipase C in pemphigus IgG-induced inositol 1,4,5-trisphosphate generation, intracellular calcium increase, and plasminogen activator secretion in DJM1 cells, a squamous cell carcinoma line. J Invest Dermatol 105: 329–333PubMedCrossRefGoogle Scholar
  23. Feliciani C, Toto P, Amerio P, Pour SM, Coscione G, Shivji G, Wang B, Sauder D (2000) In vitro and in vivo expression of interleukin-lalpha and tumor necrosis factor-alpha mRNA in pemphigus vulgaris: interleukin-lalpha and tumor necrosis factor-alpha are involved in acantholysis. J Invest Dermatol 114: 71–77PubMedCrossRefGoogle Scholar
  24. Fleischmann M, Dreno B, Litoux P, Bernard P, Celerier P (1996) Long-term interferon-alpha therapy induces autoantibodies against epidermis. Dermatology 192: 50–55PubMedCrossRefGoogle Scholar
  25. Gomi H, Kawada A, Amagai M, Matsuo I (1999) Pemphigus erythematosus: detection of anti-desmoglein-1 antibodies by ELISA. Dermatology 199: 188–189PubMedCrossRefGoogle Scholar
  26. Hashimoto T, Shafran M, Webber PA, Lazarus GS, Singer KH (1983) Anti-cell surface pemphigus autoantibody stimulates plasminogen activator activity of human epidermal cells. A mechanism for the loss of epidermal cohesion and blister formation. J Exp Med 157: 259–272Google Scholar
  27. Hashimoto K, Hashimoto T, Hiashiyama M, Nishikawa T, Garrod DR, Yoshikawa K (1994) Detection of anti-desmocollin I and II autoantibodies in two cases of of Hallopeau type pemphigus vegetans by immunoblot analysis. J Dermatol Sci 7: 100–106PubMedCrossRefGoogle Scholar
  28. Hashimoto T, Amagai M, Watanabe K, Dmochowski M, Chidgey MAJ, Yue KKM, Garrod DR, Nishikawa T (1995a) A case of pemphigus vulgaris showing reactivity with pemphigus antigens (Dsgl and Dsg3) and desmocollins J Invest Dermatol 104: 541–544Google Scholar
  29. Hashimoto T, Gamou S, Korman NJ, Boorsma DM, Stevens HP, Black MM, Bhogal BS, Chorzelski TP, Watanabe K, Amagai M (1995b) Characterization of paraneoplastic pemphigus autoantigens by immunoblot analysis. J Invest Dermatol 104: 829–834PubMedCrossRefGoogle Scholar
  30. Hashimoto T, Nishikawa T, Amagai M, Ishii K, Komori K, Kobayashi Y, Garrod DR, Chidgey MA, Miyasato M, Mori O, Kiyokawa C (1997) Human desmocollin 1 (Dsc1) is an autoantigen for the subcorneal pustular dermatosis type of IgA pemphigus. J Invest Dermatol 109: 127–131PubMedCrossRefGoogle Scholar
  31. Hertl M, Amagai M, Ishii K, Stanley J, Sundaram H, Katz SI (1998a) Recognition of desmoglein 3 by autoreactive T cells in pemphigus vulgaris patients and normals. J Invest Dermatol 110: 62–66PubMedCrossRefGoogle Scholar
  32. Hertl M (1998b) Molecular characterization of autoantibodies in pemphigus: In Conrad K, Humbel RL, Meurer M, Shoenfeld Y and Tan EM (eds.): Pathogenic and diagnostic relevance of autoantibodies. Pabst Science Publishers, BerlinGoogle Scholar
  33. Hertl M, Riechers R (1999) Analysis of the T cells that are potentially involved in autoantibody production in pemphigus vulgaris. J Dermatol 26: 748–752PubMedGoogle Scholar
  34. Hertl M (2000) Humoral and cellular autoimmunity in autoimmune bullous skin disorders. Int Arch Allergy Immunol 122: 91–100PubMedCrossRefGoogle Scholar
  35. Huilgol SC, Black MM (1995) Management of the immunobullous disorders. II. Pemphigus. Clin Exp Dermatol 20: 283–293Google Scholar
  36. Ishii K, Amagai M, Komai A, Ebharas T, Chorzelski P, Nishikawa T, Hashimoto T (1998) Desmoglein 1 and desmoglein 3 as autoimmune target of herpetiform pemphigus. J Invest Dermatol 110: 510AGoogle Scholar
  37. Iwatsuki KI, Harada H, Yokote R, Kaneko F (1995). Differences in the expression of pemphigus antigens during epidermal differentiation. Br J Dermatol 133: 209–216PubMedCrossRefGoogle Scholar
  38. Jablonska S, Chorzelski TP, Beutner EH, Chorzelska J (1975) Herpetiform pemphigus, a variable pattern of pemphigus. Int J Dermatol 14: 353–359PubMedCrossRefGoogle Scholar
  39. Jiao D, Bystryn JC (1997) Sensitivity of indirect immunofluorescence, substrate specificity, and immunoblotting in the diagnosis of pemphigus. J Am Acad Dermatol 37: 211–216PubMedCrossRefGoogle Scholar
  40. Joly P, Gilbert D, Thomine E, Delpech A, Verdier S, Lauret P, Tron F (1993) Immunofluoresence and immunoelectron microscopy analyses of a human monoclonal anti-epithelial cell surface antibody that recognizes a 185-kD polypeptide: a component of the paraneoplastic pemphigus antigen complex. J Invest Dennaiuï 101: 339–345CrossRefGoogle Scholar
  41. Joly P, Tron F, Lauret P, Delpech A, Ghohestani R, Zitouni M, Thomine E, Gilbert D (1997) Identification of a new antibody population directed against a desmosomal plaque antigen in pemphigus vulgaris and pemphigus foliaceus. J Invest Dermatol 108: 469–475PubMedCrossRefGoogle Scholar
  42. Juhasz I, Lazarus GS, Murphy GF, Shih IM, Herlyn M (1993) Development of pemphigus vulgaris-like lesions in severe combined immunodeficiency disease mice with lymphocytes from patients. J Clin Invest 92: 2401–2407PubMedCrossRefGoogle Scholar
  43. Karpati S, Amagai M, Liu WL, Dmochowski M, Hashimoto T, Horvath A (2000) Identification of desmoglein 1 as autoantigen in a patient with intraepidermal neutrophilic IgA dermatosis type of IgA pemphigus. Exp Dermatol 9: 224–228PubMedCrossRefGoogle Scholar
  44. Kazerounian S, Mahoney MG, Uitto J, Aho S (2000) Envoplakin and periplakin, the paraneoplastic pemphigus antigens, are also recognized by pemphigus foliaceus autoantibodies. J Invest Dermatol 11: 505–507Google Scholar
  45. Kim SC, Kwon YD, Lee IJ, Chang SN, Lee TG (1997) cDNA cloning of the 210-kD paraneoplastic pemphigus antigen reveals that envoplakin is a component of the antigen complex. J Invest Dermatol 109: 365–369Google Scholar
  46. Kirsner RS, Anhalt GJ, Kerdel FA (1995) Treatment with alpha interferon associated with the development of drug-induced pemphigus. Br J Dermatol 132: 474–478PubMedCrossRefGoogle Scholar
  47. Koch PJ, Mahoney MG, Ishikawa H, Pulkkinen L, Uitto J, Shultz L, Murphy GF, WhitackerMenezes D, Stanley JR (1997) Targeted disruption of the pemphigus vulgaris antigen (desmoglein 3) gene in mice causes loss of keratinocyte cell adhesion with a phenotype similar to pemphigus vulgaris. J Cell Biol 137: 1091–1102PubMedCrossRefGoogle Scholar
  48. Korman NJ, Eyre RW, Zone J, Stanley JR (1991a) Demonstration of an adhering-junction molecule (plakoglobin) in the autoantigens of pemphigus foliaceus and pemphigus vulgaris. N Engl J Med 321: 631–635CrossRefGoogle Scholar
  49. Korman NJ, Eyre RW, Zone J, Stanley JR (1991b) Drug-induced pemphigus: autoantibodies directed against the pemphigus antigen complexes are present in penicillamine-and captopril-induced pemphigus. J Invest Dermatol 96: 273–276PubMedCrossRefGoogle Scholar
  50. Kowalczyk AP, Green KJ, Stanley JR, Hashimoto T, Borgwardt JE, Anderson JE (1995) Pemphigus sera recognize conformationally sensitive epitopes in the amino-terminal region of desmoglein-1. J Invest Dermatol 105: 147–152PubMedCrossRefGoogle Scholar
  51. Kricheli D, David M, Frusic-Zlotkin M (2000) The distribution of pemphigus vulgaris IgG subclasses and reactivity with desmoglein 3 and 1 in pemphigus patients and first-degree relatives. B J Dermatol 143: 337–342CrossRefGoogle Scholar
  52. Kubo A, Yoshikawa K, Hashimoto K, Higashiyama M, Doi T, Hashimoto T, Amagai M (1997) Herpetiform pemphigus showing reactivity with pemphigus vulgaris antigen (desmoglein 3). Br J Dermatol 137: 109–113PubMedCrossRefGoogle Scholar
  53. Lever, WF (1953) Pemphigus. Medicine 32: 1–123Google Scholar
  54. Lin MS, Swartz SL, Lopez A, Ding X, Fernandez-Vina MA, Stastny P, Fairley JA, Diaz L (1997) Development and characterization of desmoglein 3-specific T cells from patients with pemphigus vulgaris. J Clin Invest 99: 31–40PubMedCrossRefGoogle Scholar
  55. Lin MS, Fu CF, Aoki V, Hans-Filho G, Riviti EA, Moraes JR, Lazaro AM, Giugice GJ, Stastny P, Diaz LA (2000) Desmoglein 1-specific T lymphocytes from patients with endemic pemphigus foliaceus (fogo selvagem). J Clin Invest 105: 207–213PubMedCrossRefGoogle Scholar
  56. Mahoney MG, Aho S, Uitto J, Stanley JR (1998) The members of the plakin family of proteins recognized by paraneoplastic pemphigus antibodies include periplakin. J Invest Dermatol 111: 308–313PubMedCrossRefGoogle Scholar
  57. Mahoney MG, Wang Z, Rothenberger KL, Koch PJ, Amagai M, Stanley JR (1999) Explanation for localization of blisters in pemphigus patients. J Clin Invest 103: 461–468PubMedCrossRefGoogle Scholar
  58. Matzner Y, Erlich HA, Brautbar C, Sanilevitch A, Landau M, Brenner S, Friedmann A (1995) Identical HLA class II alleles predispose to drug-triggered and idiopathic pemphigus vulgaris. Acta Derm Venereol 75: 12–14PubMedGoogle Scholar
  59. Mutasim DF (1999) Autoimmune bullous diseases: diagnosis and management. Dermatol Nurs 11: 15–21PubMedGoogle Scholar
  60. Nguyen VT, Ndoye A, Shultz LD, Pittelkow MR, Grando SA (2000a) Antibodies against keratinocyte antigens other than desmogleins 1 and 3 can induce pemphigus vulgarislike lesions. J Clin Invest 106: 1467–1479PubMedCrossRefGoogle Scholar
  61. Nguyen VT, Ndoye A, Grando SA (2000b) Pemphigus vulgaris antibody identifies pemphaxin. A novel keratinocyte annexin-like molecule binding acetylcholine. J Biol Chem 275: 29466–29476Google Scholar
  62. Nguyen VT, Ndoye A, Grando SA (2000c) Novel human alpha9 acetylcholine receptor regulating keratinocyte adhesion is targeted by pemphigus vulgaris autoimmunity. Am J Pathol 157: 1377–1391PubMedCrossRefGoogle Scholar
  63. Niizeki H, Inamoto N, Nakamura K, Tsuchimoto K, Hashimoto T, Nishikawa T (1994) A case of pemphigus foliaceus after interferon-alpha-2a therapy. Dermatology 189: 129–130PubMedCrossRefGoogle Scholar
  64. Nishifuji K, Amagai M, Kuwana M, Iwasaki T, Nishikawa T (2000) Detection of antigen-specific B cells in patients with pemphigus vulgaris by enzyme-linked immunospot assay: requirement of T cell collaboration for autoantibody production. J Invest Dermatol 114: 88–94PubMedCrossRefGoogle Scholar
  65. Nousari HC, Anhalt GJ (1999) Pemphigus and bullous pemphigoid. Lancet 354: 667–672 Ochsendorf FR, Schofer H, Milbradt R (1987) Pemphigus erythematosus–detection of anti-DNA antibodies. Hautarzt 1987 38: 400–403Google Scholar
  66. Ohata Y, Amagai M, Ishii K, Hashimoto T (2001) Immunoreactivity against intracellular domains of desmogleins in pemphigus. J Dermatol Sci 25: 64–71PubMedCrossRefGoogle Scholar
  67. Ongenae KC, Temmerman LJ, Vermander F (1999) Intercellular Ig A dermatosis. Eur J Dermatol 9: 85–94PubMedGoogle Scholar
  68. Oursler JR, Labib RS, Ariss-Abdo L, Burke T, O’Keefe EJ, Anhalt GJ (1992) Human autoantibodies against desmoplakins in paraneoplastic pemphigus. J Clin Invest 89: 1775–1782PubMedCrossRefGoogle Scholar
  69. Parodi A, Semino M, Gallo R, Rebora A (1993) Bullous eruption with circulating pemphigus-like antibodies following interferon-alpha therapy. Dermatology 186: 155–157PubMedCrossRefGoogle Scholar
  70. Proby C, Fujii Y, Owaribe K, Nishikawa T, Amagai M (1999) Human antibodies against HD1/plectin in paraneopolastic pemphigus. J Invest Dermatol 112: 153–156PubMedCrossRefGoogle Scholar
  71. Prost C, Intrator L, Wechsler J (1991) IgA autoantibodies bind to pemphigus vulgaris antigen in a case of intraepidermal neutrophilic IgA dermatosis. J Am Acad Dermatol 25: 846–848PubMedCrossRefGoogle Scholar
  72. Rädisch T, Riechers R, Hertl M (2001) The humanized SCID mouse model to study HLA class II-linked autoimmunity to desmoglein 3 in pemphigus (in press)Google Scholar
  73. Ramseur WL Richards F, Duggan DB (1989) A case of fatal pemphigus vulgaris in association with beta interferon and interleukin 2 therapy. Cancer 63: 2005–2007PubMedCrossRefGoogle Scholar
  74. Riechers R, Grötzinger A, Hertl M (1999) HLA class II restriction of autoreactive T cell responses in pemphigus vulgaris and potential application for a specific immunotherapy. Autoimmunity 30: 183–196PubMedCrossRefGoogle Scholar
  75. Santi CG, Maruta CW, Aoki V, Sotto MN, Rivitti EA, Diaz LA (1996) Pemphigus herpetiformis is a rare clinical expression of nonendemic pemphigus foliaceus, fogo selvagem, and pemphigus vulgaris. J Am Acad Dermatol 34: 40–46PubMedCrossRefGoogle Scholar
  76. Seishima M, Kitajima Y, Hashimoto T, Mori S, Osada K, Esaki C (1995) Pemphigus IgG, but not bullous pemphigoid IgG, causes a transient increase in intracellular calcium and inositol 1,4,5-triphosphate in DJM-1 cells, a squamous cell carcinoma line. J Invest Dermatol 104: 33–37PubMedCrossRefGoogle Scholar
  77. Senear FE, Usher B (1926) An unusual type of pemphigus combining features of lupus erythematosus. Arch Dermatol 13: 761–781CrossRefGoogle Scholar
  78. Shimizu H, Nishikawa T, Hashimoto T, Kikuchi A, Ishiko A, Masunaga T (1995) Pemphigus vulgaris and pemphigus foliaceus sera show an inversely graded binding pattern to extracellular regions of desmosomes in different layers of human epidermis. J Invest Dermatol 105: 153–159PubMedCrossRefGoogle Scholar
  79. Shirakata Y, Hashimoto K, Nishikawa T, Hanakawa Y, Amagai M (1998) Lack of mucosal involvement in pemphigus foliaceus may be due to low expression of desmoglein 1. J Invest Dermatol 110: 76–78PubMedCrossRefGoogle Scholar
  80. Sinha AA, Brautbar C, Szafer F, Friedmann A, Tzfoni E, Todd JA, Steinman L, McDevitt HO (1988) A newly characterized HLA-DQß allele associated with pemphigus vulgaris. Science 239: 1026–1029PubMedCrossRefGoogle Scholar
  81. Späth S, Riechers R, Borradori L, Zillikens D, Büdinger L, Hertl M (2001) Detection of autoantibodies of various subclasses (IgG1, IgG4, IgA, IgE) against desmoglein 3 in patients with acute onset. dnd chronic pemphigus vulgaris. Br J Dermatol (in press)Google Scholar
  82. Supapannachart N, Mutasim DF (1993) The distribution of IgA pemphigus antigen in human skin and the role of IgA anti-cell surface antibodies in the induction of intraepidermal acantholysis. Arch Dermatol 129: 605–608PubMedCrossRefGoogle Scholar
  83. Tremeau-Martinage C, Bazex J, Oksman F (1995) Immunoglobulin G subclass distribution of anti-intercellular substance antibodies in pemphigus. Ann Dermatol Venereol 122: 409–411PubMedGoogle Scholar
  84. Wallach J (1992) Intraepidermal IgA pustulosis. J Am Acad Dermatol 27: 993–1000PubMedCrossRefGoogle Scholar
  85. Wang J, Kwon J, Ding X, Fairley JA, Woodley DT, Chan LS (1997) Nonsecretory IgAl autoantibodies targeting desmosomal component desmoglein 3 in intraepidermal neutrophilic IgA dermatosis. Am J Pathol 150: 1901–1906PubMedGoogle Scholar
  86. Warren SJP, Lin MS, Giudice G, Hoffmann RG, Hans-Filho G, Aoki V, Rivitti EA, Dos Santos V, Diaz LA for the cooperative group of fogo selvagem research (2000) The prevalence of antibodies against desmoglein 1 in endemic pemphigus foliaceus in Brazil. N Engl J Med 343: 23–30CrossRefGoogle Scholar
  87. Wu H, Wang ZH, Yan A, Lyle S, Fakharzadeh S, Wahl JK, Wheelock MJ, Ishikawa H, Uitto J, Amagai M, Stanley JR (2000) Protection against pemphigus foliaceus by desmoglein 3 in neonates. N Engl J Med 343: 31–35PubMedCrossRefGoogle Scholar
  88. Wucherpfennig KW, Yu WB, Bhol K, Monos DS, Argyris E, Karr RW, Ahmed AR, Strominger JL (1995) Structural basis for major histocompatibility complex (MHC)-linked susceptibility to autoimmunity: charged residues of a single MHC binding pocket confer selective presentation of self-peptides in pemphigus vulgaris. Proc Natl Acad Sci USA 92: 11935–11939PubMedCrossRefGoogle Scholar
  89. Yasuda H, Kobayashi H, Hashimoto T, Itoh K, Yamane M, Nakamura J (2000) Subcorneal pustular dermatosis type of IgA pemphigus: demonstration of autoantibodies to desmocollin-1 and clinical review. Br J Dermatol 143: 144–148PubMedCrossRefGoogle Scholar
  90. Andrä K, Lassmann H, Bittner R, Shorny S, Fässler R, Propst F, Wiche G (1997) Targeted inactivation of plectin reveals essential function in maintaining the integrity of skin, muscle, and heart cytoarchitecture. Gen Develop 11: 3143–3156CrossRefGoogle Scholar
  91. Anhalt GJ, Diaz LA (1987) Animal models for bullous pemphigoid. Clin Dermatol 5: 117–125PubMedCrossRefGoogle Scholar
  92. Balding SD, Prost C, Diaz LA, Bernard P, Bedane C, Aberdam D, Giudice GJ (1996) Cicatri- cial pemphigoid autoantibodies react with multiple sites on the BP180 extracellular do main. J Invest Dermatol 106: 141–146PubMedCrossRefGoogle Scholar
  93. Banfield CC, Wojnarowska F, Allen J, George S, Yenning VA, Welsh KI (1998) The association of HLA-DQ7 with bullous pemphigoid is restricted to men. Br J Dermatol 138: 1085–1090PubMedCrossRefGoogle Scholar
  94. Bastuji-Garin S, Joly P, Picard-Dahan C, Bernard P, Vaillant L, Pauwels C, Salagnac V, Lok C, Roujeau JC (1996) Drugs associated with bullous pemphigoid. A case-control study. Arch Dermatol 132: 272–276Google Scholar
  95. Bernard P, Didierjean L, Denis F, Saurat JH, Bonnetblanc JM (1989) Heterogeneous bullous pemphigoid antibodies: detection and characterization by immunoblotting when absent by indirect immunofluorescence. J Invest Dermatol 92: 171–174PubMedCrossRefGoogle Scholar
  96. Bernard P, Prost C, Lecerf V, Intrator L, Combemale P, Bedane C, Roujeau JC, Revuz J, Bonnetblanc JM, Dubertret L (1990a) Studies of cicatriciel pemphigoid autoantibodies using direct immunelectron microscopy and immunoblot analysis. J Invest Dermatol 94: 630–635PubMedCrossRefGoogle Scholar
  97. Bernard P, Aucouturier P, Denis F, Bonnetblanc JM (1990b) Immunoblot analysis of IgG subclass of circulating antibodies in bullous pemphigoid. Clin Immunol Immunopath 54: 484–494CrossRefGoogle Scholar
  98. Bernard P, Vaillant L, Labeille B, BedanP C, Arheille B. Denoeux JP, Lorette G, Bonnetblanc JM, Prost C (1995) Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous diseases French study group. Arch Dermatol 131: 48–52Google Scholar
  99. Bernard P, Bedane C, Bonnetblanc JM (1997) Anti-BP180 autoantibodies as a marker of poor prognosis in bullous pemphigoid: a cohort analysis of 94 elderly patients. Br J Dermatol 136: 694–698PubMedCrossRefGoogle Scholar
  100. Borradori L, Koch PJ, Niessen CM, Erkeland S, van Leusden M, Sonnenberg A (1997) The localization of bullous pemphigoid antigen 180 (BP180) in hemidesmosomes is mediated by its cytoplasmic domain and seems to be regulated by the b4 integrin subunit. J Cell Biol 136: 1333–1347PubMedCrossRefGoogle Scholar
  101. Borradori L, Sonnenberg A (1999) Structure and function of hemidesmosomes: more than simple adhesion complexes. J Invest Dermatol 112: 411–418PubMedCrossRefGoogle Scholar
  102. Büdinger L, Borradori L, Yee C, Eming R, Ferencik S, Grosse-Wilde H, Merk HF, Yancey K, Hertl M (1998) Identification and characterization of autoreactive T cell responses to bullous pemphigoid antigen 2 in patients and healthy controls. J Clin Invest 102: 20822089Google Scholar
  103. Burton JL, Harman RM, Peachey RD, Warin RP (1978) A controlled trial of azathioprine in the treatment of pemphigoid. Br J Dermatol 99 (Suppl 16): 14PubMedCrossRefGoogle Scholar
  104. Briggaman RA, Gammon WR, Woodley DT (1985) Epidermolysis bullosa acquisita of the immunopathological type (dermolytic pemphigoid). J Invest Dermatol. 85: 79s - 84sPubMedCrossRefGoogle Scholar
  105. Chan LS, Yancey KB, Hammerberger C, Soong HK, Regezi JA, Johnson K, Cooper KD (1993) Immune-mediated subepithelial blistering diseases of mucous membranes. Arch Dermatol 129: 448–455PubMedCrossRefGoogle Scholar
  106. Chan LS, Majmudar AA, Tran HH, Meier F, Schaumburg-Lever G, Chen M, Woodley DT, Marinkovich PM (1997) Laminin-6 and laminin-5 are recognized by autoantibodies in a subset of cicatricial pemphigoid. J Invest Dermatol 108: 848–853PubMedCrossRefGoogle Scholar
  107. Chosidow O, Doppler V, Bensimon G, Joly P, Salachas F, Lacomblez L, Prost C, Camu W, Frances C, Herson S, Meininger V (2000) Bullous pemphigoid and myotrophic lateral sclerosis: a new clue for understanding the bullous disease? Arch Dermatol 136: 521–524PubMedCrossRefGoogle Scholar
  108. Chorzelski TP, Jablonska S, Beutner EH et al. Linear IgA bullous dermatosis In• Immunopathology and the Skin (Beutner EH, Chorzelski TP, Bean SF, eds). New York, NY: John Wiley and Sons Inc, 1979: 315–323Google Scholar
  109. D’Auria L, Cordiali Fei P, Ameglio F (1999) Cytokines and bullous pemphigoid. Eur Cytokine Netw 10: 123–134PubMedGoogle Scholar
  110. Delgado JC, Turbay D, Yunis EJ, Yunis JJ, Morton ED, Bhol K, Norman R, Alper CA, Good RA, Ahmed R (1996) A common major histocompatibility complex class II allele HLADQB1*0301 is present in clinical variants of pemphigoid. Proc Natl Acad Sci 93: 85698571Google Scholar
  111. Diaz LA, Ratrie H, Saunders WS, Futamura S, Squiquera HL, Anhalt GJ, Giudice GK (1990) Isolation of a human epidermal cDNA corresponding to the 180-kDa autoantigen recognized by bullous pemphigoid and herpes gestationis sera. J Clin Invest 86: 1088–1094PubMedCrossRefGoogle Scholar
  112. Domolge-Hultsch N, Gammon WR, Briggaman RA, Gil SG, Carter WG, Yancey KB (1992) Epiligrin, the major human keratinocyte ligand, is a target in both an acquired autoimmune and in inherited subepidermal blistering skin disease. J Clin Invest 90: 1628–1633CrossRefGoogle Scholar
  113. Dreno B, Sassolas B, Lacour P, Montpoint S, Lota I, Giordano F, Royer P (1993) Methylprednisolone versus prednisolone methylsulfobenzoate in pemphigoid: a comparative multicenter study. Ann Dermatol Venereol 120: 518–521PubMedGoogle Scholar
  114. Fivenson DP, Breneman DL, Rosen GB, Hersh CS, Cardone S, Mutasim (1994) Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol 6: 753–758Google Scholar
  115. Fleming TE, Korman NJ (2000) Cicatricial pemphigoid. J Am Acad Dermatol 43: 571–591PubMedCrossRefGoogle Scholar
  116. Gammon WR, Briggaman RA, Inman AO III, Queen LL, Wheeler CE (1984a) Differentiating anti-lamina lucida and anti-sublamina densa anti-BMZ antibodies by indirect immunofluorescence on 1.0 M sodium chloride-separated skin. J Invest Dermatol 82: 139–144PubMedCrossRefGoogle Scholar
  117. Gammon WR, Inman AO III, Wheeler CE, jr (1984b) Differences in complement-dependent chemotactic activity generated by bullous pemphigoid and epidermolysis bullosa acquisita immune complexes: demonstration by leukocytic attachment and organ culture methods. J Invest Dermatol 83: 57–61PubMedCrossRefGoogle Scholar
  118. Gammon WR, Kowalewski C, Chorzelski TP, Kumar V, Briggaman RA, Beutner EH (1990) Direct immunofluorescence studies of sodium chloride-separated skin in the differential diagnosis of bullous pemphigoid and epidermolysis bullosa acquisita. J Am Acad Dermatol 22: 664–670PubMedCrossRefGoogle Scholar
  119. Ghohestani RF, Nicolas JF, Kanitakis J, Claudy A (1997) Linear IgA bullous dermatosis with IgA antibodies exclusively directed against the 180- and 230-kDa epidermal antigens. J Invest Dermatol 108: 854–858PubMedCrossRefGoogle Scholar
  120. Giudice GJ, Squiquera HL, Elias PM, Diaz LA (1991) Identification of two collagen domains within the bullous pemphigoid autoantigen, BP180. J Clin Invest 87: 734–738PubMedCrossRefGoogle Scholar
  121. Giudice GJ, Emery DJ, Diaz LA (1992) Cloning and primary structural analysis of the bullous pemphigoid autoantigen BP180. J Invest Dermatol 99: 243–250PubMedCrossRefGoogle Scholar
  122. Giudice GJ, Emery DJ, Zelickson BD, Anhalt GJ, Liu Z, Diaz LA (1993) Bullous pemphigoid and herpes gestationis autoantibodies recognize a common non-collagenous site on the BP180 ectodomain. J Immunol 151: 5742–5750PubMedGoogle Scholar
  123. Giudice GJ, Wilske KC, Anhalt GJ, Fairley JA, Taylor AF, Emery DJ, Hofman RG, Diaz LA (1994) Development of an ELISA to detect anti-BP180 autoantibodies in bullous pemphigoid and herpes gestationis. J Invest Dermatol 102: 878–881PubMedCrossRefGoogle Scholar
  124. Green KJ, Virata MLA, Elgart GW, Stanley JR, Parry DAD (1992) Comparative structural analysis of desmoplakin, bullous pemphigoid antigen and plectin: members of a new gene family involved in organization of intermediate filaments. Int J Biol Macromol 14: 145–153PubMedCrossRefGoogle Scholar
  125. Guillaume JC, Vaillant L, Bernard P, Picard C, Prost C, Labeille B, Guillot B, Foldes-Pauwels C, Prigent F, Joly P (1993) Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid. Arch Dermatol 129: 49–53PubMedCrossRefGoogle Scholar
  126. Guo L, Degenstein L, Dowling J-C, Yu QC, Wollmann R, Perman B, Fuchs E (1995) Gene targeting of BPAG1: abnormalities in mechanical strength and cell migration in stratified epithelia and neurologic degeneration. Cell 81: 233–243PubMedCrossRefGoogle Scholar
  127. Haase C, Büdinger L, Borradori L, Yee C, Merk HF, Yancey KB, Hertl M (1998) Detection of IgG autoantibodies in the sera of patients with bullous and gestational pemphigoid: ELISA studies utilizing a baculovirus-encoded form of bullous pemphigoid antigen 2. J Invest Dermatol 110: 282–286PubMedGoogle Scholar
  128. Hachisuka H, Kurose K, Karashima T, Mori O, Maeyama Y (1996) Serum from elderly individuals contains anti-basement membrane zone antibodies. Arch Dermatol 132: 1201–1205PubMedCrossRefGoogle Scholar
  129. Hall RPI, Murray JC, McCord MM, Rico JM, Streilein RD (1993) Rabbits immunized with a peptide encoded for by the 230-kd bullous pemphigoid antigen cDNA develop an enhanced inflammatory response to UVB irradiation: a potential animal model for bullous pemphigoid. J Invest Dermatol 101: 9–14PubMedCrossRefGoogle Scholar
  130. Hashimoto T, Ishiko, A, Shimizu H, Tanaka T, Dodd HJ, Bhogal BS, Black MM, Nishikava T (1996) A case of linear IgA bullous dermatosis with IgA anti-type VII collagen autoantiboies. Br J Dermatol 134: 336–339PubMedCrossRefGoogle Scholar
  131. Hirako Y, Usukura J, Uematsu J, Hashimoto T, Kitajima Y, Owaribe K (1998) Cleavage of BP180, a 180-kDa bullous pemphigoid antigen, yields a 120-kDa collagenous extracellular polypeptide. J Biol Chem 273: 9711–9717PubMedCrossRefGoogle Scholar
  132. Hopkinson SB, Riddelle KS, Jones JCR (1992) Cytoplasmic domain of the 180-kD bullous pemphigoid antigen, a hemidesmosomal component: molecular and cell biologic characterization. J Invest Dermatol 99: 264–270PubMedCrossRefGoogle Scholar
  133. Hopkinson SB, Baker SE, Jones JCR (1995) Molecular genetic studies of a human epidermal autoantigen (the 180-kD bullous pemphigoid antigen/BP180): identification of functionally important sequences within the BP180 molecule and evidence for an interaction between BP180 and a6 integrin. J Cell Biol 130: 117–125PubMedCrossRefGoogle Scholar
  134. Ide A, Hashimoto T, Amagai M, Tanaka M, Nishikawa T (1995) Detection of autoantibodies against the bullous pemphigoid and pemphigus antigens by an enzyme-linked immunosorbent assay using the bacterial recombinant proteins. Exp Dermatol 5: 112–116CrossRefGoogle Scholar
  135. Joly P, Picard C, Roujeau JC, Delaporte E, Dreno B, Bedane C, Tancrede-Bohin E, Plantin P, D’Incan M, Sassolas B, Saïag P, Lok C, Labeille B, Pauwels C, Chosidow O, Loche F, Guillaume JC, Vaillant L, Bernard P (2000) Comparaison de deux stratégies thérapeutiques: corticothérapie locale versus corticothérapie générale dans le traitement de la pemphigoide bulleuse (Abstract). Ann Dermatol Venereol suppl 4: 4S4Google Scholar
  136. Jonkman MF, de Jong MC, Heeres K, Pas HH, van der Meer JB, Owaribe K, Martinez de Velasco AM, Niessen CM, Sonnenberg A (1995) 180-kD bullous pemphigoid antigen(BP180) is deficient in generalized atrophic benign epidermolysis bullosa. J Clin Invest 95: 1345–1352Google Scholar
  137. Jenkins RE, Shornick JK, Black MM (1993) Pemphigoid gestationis. J Eur Acad Dermatol 2: 163–173CrossRefGoogle Scholar
  138. Jordon RE, Beutner EH, Witebsky E, Blumental G, Hale WC, Lever WC (1967) Basement zone antibodies in bullous pemphigoid. J Am Med Assoc 200: 751–756CrossRefGoogle Scholar
  139. Jung M, Kippes W, Messer G, Zillikens D, Rzany B (1999) Increased risk of bullous pemphigoid in male and very old patients: a population based study on incidence. J Am Acad Dermatol 41: 266–268PubMedCrossRefGoogle Scholar
  140. Kawahara Y, Amagai M, Ohata Y, Ishii K, Hasegawa Y, Hsu R, Yee C, Yancey KB, Nishikawa T (1998) A case of cicatricial pemphigoid with simultaneous IgG autoantibodies against the 180 kd bullous pemphigoid antigen and laminin 5. J Am Acad Dermatol 38: 624–627PubMedCrossRefGoogle Scholar
  141. Korman NJ (1987) Bullous pemphigoid. J Am Acad Dermatol 16: 907–924PubMedCrossRefGoogle Scholar
  142. Korman NJ (2000) New and emerging therapies in the treatment of blistering diseases. Dermatol Clin 18: 127–137PubMedCrossRefGoogle Scholar
  143. Labib RS, Anhalt GJ, Patel HP, Mutasim DF, Diaz LA (1986) Molecular heterogeneity of the bullous pemphigoid antigens as detected by immunoblotting. J Immunol 136: 1231–1235PubMedGoogle Scholar
  144. Laffitte E, Borradori L (2001a) Fiche thérapeutique: prise en charge de la pemphigoïde bulleuse. Ann Dermatol Venerol. 128: 677–680Google Scholar
  145. Laffitte E, Favre B, Fontao L, Riou S, Jaunin F, Tamm K, Saurat J-H, Borradori L (2001b) Plectin, an unusual target in bullous pemphigoid. Br J Dermatol. 144: 136PubMedCrossRefGoogle Scholar
  146. Lever WF (1953) Pemphigus. Medicine 32: 1–123Google Scholar
  147. Li K, Guidice GJ, Tamai K, Do HC, Sawamura D, Diaz LA, Uitto J (1992) Cloning of partial cDNA for mouse 180-kDa bullous pemphigoid antigen (BPAG2), a highly conserved collagenous protein of the cutaneous basement membrane zone. J Invest Dermatol 99: 258–263PubMedCrossRefGoogle Scholar
  148. Lin MS, Gharia MA, Swartz SJ, Diaz LA, Giudice GJ (1999) Identification and characterization of epitopes recognized by T lymphocytes and autoantibodies from patients with herpes gestationis J Immunol 162: 4999–4997Google Scholar
  149. Lindelöf B, Islam N, Eklund G, Arfors L (1990) Pemphigoid and cancer. Arch Dermatol 126: 66–68PubMedCrossRefGoogle Scholar
  150. Liu HH, Su DWP, Rogers RS III (1986) Clinical variants of pemphigoid. Int J Dermatol 25: 17–27PubMedCrossRefGoogle Scholar
  151. Liu Z, Diaz LA, Troy JL, Taylor AF, Emery DJ, Fairley JA, Giudice GJ (1993) A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest 92: 2480–2488PubMedCrossRefGoogle Scholar
  152. Liu Z, Shapiro SD, Zhou X, Twining SS, Senior RM, Giudice GJ, Fairley JA, Diaz LA (2000a) A critical role for neutrophil elastase in experimental bullous pemphigoid. J Clin Invest 105: 113–123PubMedCrossRefGoogle Scholar
  153. Liu Z, Chen R, Diaz L, Senior R, Werb Z (2000b) Plasminogen/plasmin in experimental bullous pemphigoid ( Abstract ). J Invest Dermatol 114: 778Google Scholar
  154. Luke MC, Darling TN, Hsu R, Summers RM, Smith JA, Solomon BI, Thomas GR, Yancey KB (1999) Mucosal morbidity in patients with epidermolysis bullosa acquisita. Arch Dermatol 135: 954–959PubMedCrossRefGoogle Scholar
  155. Masouyé I, Schmid E, Didierjean L, Abba Z, Saurat JH (1989) Bullous pemphigid and multiple sclerosis: more than a coincidence? Report of three cases. J Am cad Dermatol 21: 63–68CrossRefGoogle Scholar
  156. McGrath JA, Gatalica B, Christiano AM, Li K, Owaribe K, McMillan JR, Eady RA, Uitto J (1995) Mutations in the 180-kD bullous pemphigoid antigen (BPAG2), a hemidesmosomal transmembrane collagen (COL17A1), in generalized atrophic benign epidermolysis bullosa. Nature Genet 11: 83–86PubMedCrossRefGoogle Scholar
  157. Miller JE, Rico JM, Hall RP (1993) IgG antibodies from patients with bullous pemphigoid bind to fusion proteins encoded by BPAg1 cDNA. J Invest Dermatol 101: 779–782PubMedCrossRefGoogle Scholar
  158. Morel P, Guillaume JC (1984) Treatment of bullous pemphigoid with prednisolone only: 0.75 mg/kg/day versus 1.25 mg/kg/day. A multicenter randomized study Ann Dermatol Venereol 111: 925–928Google Scholar
  159. Morrison LH, Labib RS, Zone JJ, Diaz LA, Anhalt GJ (1988) Herpes gestationis autoantibodies recognize a 180-kD human epidermal antigen. J Clin Invest 8: 2023–2026CrossRefGoogle Scholar
  160. Mueller S, Klaus-Kovtun V, Stanley JR (1989) A 230 kD basic protein is the major bullous pemphigoid antigen. J Invest Dermatol 92: 32–38CrossRefGoogle Scholar
  161. Nemeth AJ, Klein AD, Gould EW, Schachner LA (1991) Childhood bullous pemphigoid. Clini- cal and immunologic features, treatment, and prognosis. Arch Dermatol 127: 378–386Google Scholar
  162. Olivry T, Mirsky ML, Singleton W, Dunston SM, Borillo AK, Xu L, Traczyk T, Rosolia DL, Chan LS (2000) A spontaneously rising porcine model of bullous pemphigoid. Arch Dermatol Res 292: 37–45PubMedCrossRefGoogle Scholar
  163. Okazaki A, Miyagawa S, Yamashina Y, Kitamura W, Shirai T (2000) Polymorphisms of HLADR and -DQ genes in Japanese patients with bullous pemphigoid. J Dermatol 27: 149–156PubMedGoogle Scholar
  164. Pas HH, Kloosterhuis GJ, Heeres K, van der Meer JB, Jonkman MF (1997) Bullous pemphigoid and linear IgA dermatosis sera recognize a similar 120-kDa keratinocyte collagenous glycoprotein with antigenic cross-reactivity to BP180. J Invest Dermatol 108: 423–429PubMedCrossRefGoogle Scholar
  165. Perriard J, Jaunin F, Favre B, Büdinger L, Hertl M, Saurat J-H, Borradori L (1999) IgG autoantibodies from bullous pemphigoid (BP) patients bind antigenic sites on both the extracellular and the intracellular domain of the BP antigen 180. J Invest Dermatol 112: 141–147PubMedCrossRefGoogle Scholar
  166. Rico MJ, Korman NJ, Stanley JR, Tanaka T, Hall RP (1990) IgG antibodies from patients with bullous pemphigoid bind to localized epitopes on synthetic peptides encoded bullous pemphigoid antigen cDNA. J Immunol 145: 3728–3733PubMedGoogle Scholar
  167. Rieckhoff-Cantoni L, Bernard P, Didierjean L, Imhof K, Kinloch-de-Loes S, Saurat JH (1992) Frequency of bullous pemphigoid-like antibodies as detected by Western immunoblot analysis in pruritic dermatoses. Arch Dermatol 128: 791–794PubMedCrossRefGoogle Scholar
  168. Romagnani S (1992) Human Thl and Th2 subsets: regulation of differentiation and role in protection and immunopathology. Int Arch Allergy Appl Immunol 98: 279–285CrossRefGoogle Scholar
  169. Roujeau JC, Lok C, Bastuji-Garin S, Mhalla S, Enginger V, Bernard P (1998) High risk of death in elderly patients with extensive bullous pemphigoid. Arch Dermatol 134: 465–469PubMedCrossRefGoogle Scholar
  170. Sawamura D, Li K, Chu ML, Uitto J (1991) Human bullous pemphigoid antigen (BPAG1). Amino acid sequences deduced from cloned cDNAs predict biologically important peptide segments and protein domains. J Biol Chem 266: 17784–17790Google Scholar
  171. Schäcke H, Schumann H, Hammami-Hauasli N, Raghunath M, Bruckner-Tuderman L (1998) Two forms of collagen XVII in keratinocytes. A full-length transmembrane protein and a soluble ectodomain. J Biol Chem 273: 25937–25943Google Scholar
  172. Schmidt E, Obe K, Brocker EB, Zillikens D (2000a) Serum levels of autoantibdies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol 136: 174–178PubMedCrossRefGoogle Scholar
  173. Schmidt E, Reimer S, Kruse N, Jainta S, Brocker EB, Marinkovich MP, Giudice GJ, Zillikens D (2000b) Autoantibodies to BP180 associated with bullous pemphigoid release interleukin-6 and interleukin-8 from cultured human keratinocytes. J Invest Dermatol 115: 842–848PubMedCrossRefGoogle Scholar
  174. Skaria M, Jaunin F, Hunziker T, Riou S, Schumann H, Bruckner-Tuderman L, Hertl M, Bernard P, Saurat JH, Favre B, Borradori L (2000) IgG autoantibodies from bullous pemphigoid patients recognize multiple antigenic reactive sites located predominantly within the B and C subdomain of the COOH-terminus of BP230. J Invest Dermatol 114: 998–1004PubMedCrossRefGoogle Scholar
  175. Shornick JK (1993) Herpes gestationis. Dermatol Clin 11: 527–533PubMedGoogle Scholar
  176. Stahle-Bäckdahl M, Inoue M, Giudice GJ, Parks WC (1994) 92-kD gelatinase is produced by eosinophils at the site of blister formation in bullous pemphigoid and cleaves the extra-cellular domain of recombinant 180 kD in bullous pemphigoid autoantigen. J Clin Invest 93: 2022–2230Google Scholar
  177. Stanley JR, Hawley-Nelson P, Yuspa SH, Shevach EM, Katz SI (1981) Characterization of bullous pemphigoid antigen: a unique basement membrane protein of stratified squamous epithelia. Cell 24: 897–903PubMedCrossRefGoogle Scholar
  178. Stanley JR, Tanaka T, Mueller S, Klaus-Kovtun V, Roop D (1988) Isolation of complementary DNA for bullous pemphigoid antigen by use of patients’ autoantibodies. J Clin Invest 82: 1864–1870PubMedCrossRefGoogle Scholar
  179. Tanaka M, Hashimoto T, Amagai M, Shimizu N, Ikeguchi N, Tsubata T, Hasegawa A, Miki K, Nishikawa T (1991) Characterization of bullous pemphigoid antibodies by use of recombinant bullous pemphigoid antigen proteins. J Invest Dermatol 97: 725–728PubMedCrossRefGoogle Scholar
  180. Tanaka M, Hashimoto T, Dykes PJ, Nishikawa T (1996) Clinical manifestations in 100 Japanese bullous pemphigoid cases in relation to autoantigen profiles. Clin Exp Dermatol 21: 23–27PubMedCrossRefGoogle Scholar
  181. Taylor G, Yenning V, Wojnarowska F, Welch K (1993) Bullous pemphigoid and autoimmunity. J Am Acad Dermatol 29: 181–184PubMedCrossRefGoogle Scholar
  182. Trüeb RM, Didierjean L, Fellas A, Avraam E, Borradori L (1999) Childhood bullous pemphigoid. Report of a case with characterization of the targeted antigens. J Am Acad Dermatol 40: 338–344Google Scholar
  183. Tyagi S, Bhol K, Natarajan K, Livir-Rallatos C, Foster CS, Ahmed AR (1996) Ocular cicatricial pemphigoid antigen: partial sequence and biochemical characterization. Proc Natl Acad Sci USA 93: 14714–14719PubMedCrossRefGoogle Scholar
  184. Vaillant L, Bernard P, Joly P, Labeille B, Bedane C, Arbeille B, Thomine B, Bertrand B, Lok C, Roujeau JC (1998) Evaluation of clinical criteria for diagnosis of bullous pemphigoid. French bullous study group. Arch Dermatol 134: 1075–1080Google Scholar
  185. Vanderlugt CJ, Miller SD (1996) Epitope spreading. Curr Opin Immunol 8: 831–836 Vassileva S (1998) Clin Dermatol 16: 379–387Google Scholar
  186. Verraes S, Polette M, Borradori L, Hornbeck W, Bernard P (2000) Action des protéases sur l’antigène cible BP180 au cours de la pemphigoïde bulleuse (abstract). Ann Dermatol Venereol 127: 4S2Google Scholar
  187. Venning VA, Millard PR, Wojnarowska F (1989) Dapsone as first line therapy for bullous pemphigoid. Br J Dermato 120: 83–92CrossRefGoogle Scholar
  188. Yenning VA, Wojnarowska F (1990) The association of bullous pemphigoid and malignant disease: a case control study. Br J Dermatol 123: 439–445CrossRefGoogle Scholar
  189. Wakugawa M, Nakamura K, Hino H, Toyama K, Hattori N, Okochi H, Yamada H, Hirai K, Tamaki K, Furue M (2000) Elevated levels of eotaxin and interleukin-5 in blister fluid of bullous pemphigoid: correlation with tissue eosinophilia. Br J Dermatol 143: 112–116PubMedCrossRefGoogle Scholar
  190. Wojnarowska F, Marsden RA, Bhogal B, Black MM (1988) Chronic bullous disease of childhood, childhood cicatricial pemphigoid, and linear IgA disease of adults. A comparative study demonstrating clinical and immunological overlap. J Am Acad Dermatol 19: 792805Google Scholar
  191. Wojnarowska F, Whitehead P, Leigh IM, Bhogal BS, Black MM (1991) Identification of the target antigen in chronic bullous disease of childhood and linear IgA disease of adults. Br J Dermatol 124: 157–162PubMedCrossRefGoogle Scholar
  192. Woodley DT, Briggaman RA, O’Keefe EJ, Inman AO, Queen LL, Gammon WR (1984) Identification of the skin basement-membrane autoantigen in epidermolysis bulloua acquisita. N Engl J Med 310: 1007–1013PubMedCrossRefGoogle Scholar
  193. Zillikens D, Mascaro JM, Rose PA, et al (1997a) A highly sensistive enzyme-linked immunosorbent assay for the detection of circulating autoantibodies in patients with bullous pemphigoid. J Invest Dermatol 109: 679–683PubMedCrossRefGoogle Scholar
  194. Zillikens D, Rose PA, Balding SD, Liu Z, Olague-Marchan M, Diaz LA, Giudice GJ (1997b) Tight clustering of extracellular BP180 epitopes recognized by bullous pemphigoid autoantibodies. J Invest Dermatol 109: 573–579PubMedCrossRefGoogle Scholar
  195. Zone JJ, Taylor TB, Meyer LJ, Petersen MJ (1998) The 97-kDa linear IgA bullous disease antigen is identical to a portion of the extracellular domain of the 180-kDa bullous pemphigoid antigen, BPAG2. J Invest Dermatol 110: 207–210PubMedCrossRefGoogle Scholar
  196. Ackerman AB, Chongchitnant N, Sanchez J, Guo Y, Bennin B, Reichel M, Randall MB (1997) Histologic diagnosis of inflammatory skin diseases, 2nd ed. Williams and Wilkins, Baltimore, pp 271–278Google Scholar
  197. Alexander O’D (1963) The treatment of dermatitis herpetiformis with heparin. Br J Dermatol 75: 289–293CrossRefGoogle Scholar
  198. Beutner EH, Baughman RD, Austin BM, Plunkett RW, Binder WL (2000) A case of dermatitis herpetiformis with IgA endomysial antibodies but negative direct immunofluorescent findings. J Am Acad Dermatol 43: 329–332PubMedCrossRefGoogle Scholar
  199. Brow J, Parker F, Weinstein W, Rubin CE (1971) The small intestinal mucosa in dermatitis herpetiformis: severity and distribution of the small intestinal lesion and associated malabsorption. Gastroenterology 60: 355–361PubMedGoogle Scholar
  200. Collin P, Pukkala E, Reunala T (1996) Malignancy and survival in dermatitis herpetiformis: a comparison with coeliac disease. Gut 38: 528–530PubMedCrossRefGoogle Scholar
  201. Cormane RH (1967) Immunofluorescent studies of the skin in lupus erythematosus and other diseases. Pathologica Eur 2: 170–180Google Scholar
  202. Corrao G, Corazza GR, Andreani ML, Torchio P, Valentini RA, Galatola G, Quaglino D, Gasbarrini G, di Orio F (1994) Serological screening of coeliac disease: choosing the optimal procedure according to various prevalence values. Gut 35: 771–775PubMedCrossRefGoogle Scholar
  203. Costello M (1940) Dermatitis herpetiformis treated with sulfapyridine. Arch Dermatol Syphilol 41: 134Google Scholar
  204. Chorzelski TP, Jablonska S, Beutner EH, Bear SF, Furey NL (1979) Linear IgA bullous dermatosis. In: Beutner EH, Chorzelski TP, Bear SF (eds) Immunopathology of the skin. 2nd ed. John Wiley and Sons; New York, pp 315–323Google Scholar
  205. Chorzelski TP, Sulej J, Tchorzewska H, Jablonska S, Beutner EH, Kumar V (1983) IgA class endomysium antibodies in dermatitis herpetiformis and coeliac disease. Ann N Y Acad Sci 4: 325–334CrossRefGoogle Scholar
  206. Dieterich W, Ehnis T, Bauer M, Donner P, Volta U, Riecken EO, Schuppan D (1997) Identification of tissue transglutaminase as the autoantigen of celiac disease. Nature Med 3: 797–801PubMedCrossRefGoogle Scholar
  207. Dieterich W, Laag E, Schöpper H, Volta U, Ferguson A, Gillett H, Riecken EO, Schuppan D (1998) Autoantibodies to tissue transglutaminase as predictors of celiac disease. Gastroenterology 115: 1317–1321PubMedCrossRefGoogle Scholar
  208. Dieterich W, Laag E, Bruckner-Tuderman L, Reunala T, Kârpâti S, Zâgoni T, Riecken EO, Schuppan D (1999) Antibodies to tissue transglutaminase as serologic markers in patients with dermatitis herpetiformis. J Invest Dermatol 113: 133–136PubMedCrossRefGoogle Scholar
  209. Duhring LA (1884) Dermatitis herpetiformis. JAMA 3: 225–229CrossRefGoogle Scholar
  210. Ermacora E, Prampolini L, Tribbia G, Pezzoli G, Gelmetti C, Cucchi G, Tettamanti A, Giunta A, Gianotti F (1986) Long-term follow-up of dermatitis herpetiformis in children. J Am Acad Dermatol 15: 23–30CrossRefGoogle Scholar
  211. Fraser NG, Kerr NW, Donald D (1973) Oral lesions in dermatitis herpetiformis. Br J Dermatol 89: 439–450PubMedCrossRefGoogle Scholar
  212. Fry L, Keir P, McMinn RMH, Cowan JD, Hoffbrand AV (1967) Small-intestinal structure and function and haematological changes in dermatitis herpetiformis. Lancet II: 729–734Google Scholar
  213. Fry L, Seah PP, Riches DJ, Hoffbrand AV (1973) Clearance of skin lesions in dermatitis herpetiformis after gluten withdrawal. Lancet I: 288–291Google Scholar
  214. Fry L, Leonard JN, Swain F, Tucker WFG, Haffenden G, Ring N, McMinn RMH (1982) Longterm follow-up of dermatitis herpetiformis with and without dietary gluten withdrawal. Br J Dermatol 107: 631–640PubMedCrossRefGoogle Scholar
  215. Fry L (1988) Fine points in the management of dermatitis herpetiformis. Semin Dermatol 7: 206–211PubMedGoogle Scholar
  216. Fry L (1995) Dermatitis herpetiformis. Baillière’s Gastroenterol 9: 371–393CrossRefGoogle Scholar
  217. Garioch JJ, Lewis HM, Sargent SA, Leonard JN, Fry L (1994) 25 years’ experience of gluten-free diet in the treatment of dermatitis herpetiformis. Br J Dermatol 131: 541–545Google Scholar
  218. Graeber M, Baker BS, Garioch JJ (1993) The role of cytokines in the generation of skin lesions in dermatitis herpetiformis. Br J Dermatol 129: 530–532PubMedCrossRefGoogle Scholar
  219. Hall MA, Lanchbury JSS, Bolsover WJ, Ciclitira JP (1991) HLA association with dermatitis herpetiformis is accounted for by a cis or transassociated DQ heterodimer. Gut 32: 487490Google Scholar
  220. Hardman CM, Garioch JJ, Leonard JN, Thomas HJ, Walker MM, Lortan JE, Lister A, Fry L (1997) Absence of toxicity of oats in patients with dermatitis herpetiformis. N Engl J Med 337: 1884–1887PubMedCrossRefGoogle Scholar
  221. Hendrix JD, Karen L, Mangum MT, Zone JJ, Gammon WR (1990) Cutaneous IgA deposits in bullous diseases function as ligands to mediate adherence of activated neutrophils. J Invest Dermatol 94: 667–672PubMedCrossRefGoogle Scholar
  222. Kadunce DP, Meyer LJ, Zone JJ (1989) IgA class antibodies in dermatitis herpetiformis: reaction with tissue antigens. J Invest Dermatol 93: 253–258PubMedCrossRefGoogle Scholar
  223. Kârpâti S, Torok E, Kosnai I (1986) Discrete palmar and plantar symptoms in children with dermatitis herpetiformis Duhring. Cutis 3: 184–187Google Scholar
  224. Kârpâti S, Meurer M, Stolz W, Schrallhammer K, Krieg T, Braun-Falco O (1990) Dermatitis herpetiformis bodies, Arch Dermatol 126: 1469–1474PubMedCrossRefGoogle Scholar
  225. Lear JT, Neary RH, Jones P, Fitzgerald DA, English JS (1997) Risk factors for ischaemic heart disease in patients with dermatitis herpetiformis. J R oc Med ÿU: 24 t-249Google Scholar
  226. Leonard J, Haffenden G, Tucker W, Unsworth J, Swain F, McMinn R, Holborow J, Fry L(1983) Gluten challenge in dermatitis herpetiformis. N Engl J Med 308: 816–819Google Scholar
  227. Lewis HM, Reunala TL, Garioch JJ, Leonard JN, Fry JS, Collin P, Evans D, Fry L (1996) Protective effect of gluten-free diet against development of lymphoma in dermatitis herpetiformis. Br J Dermatol 135: 363–367PubMedCrossRefGoogle Scholar
  228. Olkarinen AL, Reunala T, Zone JJ, Kilstala U, Uitto J (1986) Proteolytic enzymes in blister fluids from patients with dermatitis herpetiformis. Br J Dermatol 114: 295–302CrossRefGoogle Scholar
  229. Marks J, Shuster S, Watson AJ (1966) Small bowel changes in dermatitis herpetiformis. Lancet II: 1280–1282Google Scholar
  230. McFadden JP, Leonard JN, Powles AV, Rutman AJ, Fry L (1989) Sulphamethoxypyridazine for dermatitis herpetiformis, linear IgA disease and cicatricial pemphigoid. Br J Dermatol 121: 759–762PubMedCrossRefGoogle Scholar
  231. Mobacken H, Kastrup W, Nilsson L. (1984) Incidence and prevalence of dermatitis herpetiformis in Western Sweden. Acta Derm Venereol 64: 400–404PubMedGoogle Scholar
  232. Prendiville JS, Esterly NB (1991) Childhood dermatits herpetiformis. Clin Dermatol 9: 375–381PubMedCrossRefGoogle Scholar
  233. Raghunath M, Höpfner B, Aeschlimann D, Liithi U, Meuli M, Altermatt S, Gobet R, BrucknerTuderman L, Steinmann B (1996) Cross-linking of the dermo-epidermal junction of skin regenerating from keratinocyte autografts. J Clin Invest 98: 1174–1184PubMedCrossRefGoogle Scholar
  234. Reunala T, Collin P (1997) Diseases associated with dermatitis herpetiformis. Br J Dermatol 136: 315–318PubMedCrossRefGoogle Scholar
  235. Reunala T, Collin P, Holm K, Pikkarainen P, Miettinen A, Vuolteenaho N, Maki M (1998) Tolerance to oats in dermatitis herpetiformis. Gut 43: 490–493PubMedCrossRefGoogle Scholar
  236. Rose C, Dieterich W, Bröcker EB, Schuppan D, Zillikens D (1999) Circulating autoantibodies to tissue transglutaminase differentiate patients with dermatitis herpetiformis from those with linear IgA disease. J Am Acad Dermatol 41: 957–961.PubMedCrossRefGoogle Scholar
  237. Mitten A, Goos M (1989) Palmoplantar purpura in Duhring’s herpetiform dermatitis. Hautarzt 40: 640–643Google Scholar
  238. Sachs JA, Awad J, McCloskey D, Navarrete C, Festenstein H, Elliot E, Walker-Smith JA, Griffiths CE, Leonard JN, Fry L (1986) Different HLA associated gene combinations contribute to susceptibility for coeliac disease and dermatitis herpetiformis. Gut 27: 515–520PubMedCrossRefGoogle Scholar
  239. Sârdy M, Odenthal U, Kârpâti S, Paulsson M, Smyth N (1999) Recombinat human tissue transglutaminase ELISA for the diagnosis of gluten-sensitive enteropathy. Clin Chem 45: 2142–2149PubMedGoogle Scholar
  240. Schuppan D (2000) Current concepts of celiac disease pathogenesis. Gastroenterology 119: 234–242PubMedCrossRefGoogle Scholar
  241. Seissler J, Borns S, Wohlrab U, Morgenthaler NG, Mothes T, Boehm BO, Scherbaum WA (1999) Antibodies to human tissue transglutaminase measured by radioligand assay: evidence for high diagnostic sensitivity for celiac disease. Horm Metab Res 31: 375–379PubMedCrossRefGoogle Scholar
  242. Silvers DN, Juhlin EA, Berczeller PH, McSorley J (1980) Treatment of dermatitis herpetiformis with colchicine. Arch Dermatol 116: 1373–1374PubMedCrossRefGoogle Scholar
  243. Shah SAA, Ormerod AD (2000) Dermatitis herpetiformis effectively treated with heparin, tetracycline and nicotinamide. Clin Exp Dermatol 25: 204–205PubMedCrossRefGoogle Scholar
  244. Smith JB, Tulloch JE, Meyer LJ, Zone JJ (1992) The incidence and prevalence of dermatitis herpetiformis in Utah. Arch Dermatol 128: 1608–1610PubMedCrossRefGoogle Scholar
  245. Sulkanen S, Halttunen T, Laurila K, Kolho KL, Korponay-Szabo IR, Sarnesto A, Savilahti E, Collin P, Mäki M (1998) Tissue transglutaminase autoantibody enzyme-linked immunosorbent assay in detecting celiac disease. Gastroenterology 115: 1322–1328PubMedCrossRefGoogle Scholar
  246. Swerdlow AJ, Whittaker S, Carpenter LM, English JSC (1993) Mortality and cancer incidence in patients with dermatitis herpetiformis: a cohort study. Br J Dermatol 129: 140–144PubMedCrossRefGoogle Scholar
  247. Tan CC, Sale JE, Brammer C, Irons RP, Freeman JG (1996) A rare case of dermatitis herpetiformis requiring parenteral heparin for long-term control. Dermatology 192: 185–186PubMedCrossRefGoogle Scholar
  248. Van der Meer JB (1969) Granular deposits of immunoglobulins in the skin of patients with dermatitis herpetiformis. Br J Dermatol 81: 493–503PubMedCrossRefGoogle Scholar
  249. Ventura A, Magazzu G, Greco L for the SIGEP study group for autoimmune disorders in celiac disease (1999) Duration of exposure to gluten and risk for autoimmune disorders in patients with celiac disease. Gastroenterology 117: 297–303CrossRefGoogle Scholar
  250. Zillikens D, Kawahara Y, Ishiko A, Shimizu H, Mayer J, Rank CV, Liu Z, Giudice GJ, Tran HH, Marinkovich MP, Bröcker EB, Hashimoto T (1996) A novel subepidermal blistering disease with autoantibodies to a 200-kDa antigen of the basement membrane zone. J Invest Dermatol 106: 1333–1336PubMedCrossRefGoogle Scholar
  251. Zemtsov A, Neldner K (1993) Successful treatment of dermatitis herpetiformis with tetracycline and nicotinamide in a patient unable to tolerate dapsone. J Am Acad Dermatol 28: 505–506PubMedCrossRefGoogle Scholar
  252. Zone JJ, Carioto LA, LaSalle BA, Peterson MJ (1995) Granular IgA is decreased or absent in never involved skin in dermatitis herpetiformis. Clin Res 33: 699 AGoogle Scholar
  253. Ackerman AB, Chongchitnant N, Sanchez J, Guo Y, Benin B, Reichel M, Randall MB (1997) Histologic diagnosis of inflammatory skin diseases: an algorithmic method based on pattern analysis. 2nd ed. Williams and Wilkins, BaltimoreGoogle Scholar
  254. Arpey CJ, Elewski BE, Moritz DK, Gammon WR (1991) Childhood epidermolysis bullosa acquisita: report of three cases and review of literature. J Am Acad Dermatol 24: 706–714PubMedCrossRefGoogle Scholar
  255. Bauer JW, Schaeppi H, Metze D, Muss W, Pohla-Gubo G, Hametner R, Ruckhofer J, Grabner G, Hintner H (1999) Ocular involvement in IgA-epidermolysis bullosa acquisita. Br J Dermatol 141: 887–892PubMedCrossRefGoogle Scholar
  256. Bernard P, Vaillant L, Labeille B, Bedane C, Arbeille B, Denoeux JP, Lorette G, Bonnetblanc JM, Prost C (1995) Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Arch Dermatol 131: 48–52PubMedCrossRefGoogle Scholar
  257. Borradori L, Caldwell JB, Briggaman RA, Burr CE, Gammon WR, James WD, Yancey KB (1995) Passive transfer of autoantibodies from a patient with mutilating epidermolysis bullosa acquisita induces specific alterations in the skin of neonatal mice. Arch Dermatol 131: 590–595PubMedCrossRefGoogle Scholar
  258. Briggaman RA, Wheeler CE Jr (1975) The epidermal-dermal junction. J Invest Dermatol 65: 71–84PubMedCrossRefGoogle Scholar
  259. Briggaman RA, Schechter NM, Fraki J, Lazarus GS (1980) Degradation of the epidermal-dermal junction by proteolytic enzymes from human skin and human polymorphonuclear leukocytes. J Exp Med 160: 1027–1042CrossRefGoogle Scholar
  260. Bruckner-Tuderman L, Nilssen O, Zimmermann DR, Dours-Zimmermann MT, Kalinke DU, Gedde-Dahl TJr, Winberg JO (1995) Immunohistochemical and mutation analyzes demonstrate that procollagen VII is processed to collagen VII through removal of the NC-2 domain. J Cell Biol 131: 551–559PubMedCrossRefGoogle Scholar
  261. Burgeson RE (1993) Type VII collagen, anchoring fibrils, and epidermolysis bullosa. J Invest Dermatol 101: 252–255PubMedCrossRefGoogle Scholar
  262. Callot-Mellot C, Bodemer C, Caux F, Bourgault-Villada I, Fraitag S, Goudie G, Heller M, de Prost Y, Prost C (1997) Epidermolysis bullosa aquisita in childhood. Arch of Dermatol 133: 1122–1126CrossRefGoogle Scholar
  263. Camara A, Becherel PA, Bussel A, Lagrange S, Chosidow O, Joly P, Piette JC, Frances C (1999) Resistant acquired bullous epidermolysis with severe ocular involvement: the success of extracorporeal photochemotherapy. Annal Dermatol Venereol 126: 612–615Google Scholar
  264. Chan LS, Fine JD, Briggaman RA, Woodley DT, Hammerberg C, Drugge RJ, Cooper KD (1993) Identification and partial characterization of a novel 105-kDalton lower lamina lucida autoantigen associated with a novel immune-mediated subepidermal blistering disease. J Invest Dermatol 101: 262–267PubMedCrossRefGoogle Scholar
  265. Chan LS, Woodley DT (1996) Pemphigoid: Bullous and cicatricial. In Current Therapy in Allergy, Immunology and Rhematology, 5th ed, edited by LM Lichtenstein, AS Fauci Mosby, St Louis, p 93Google Scholar
  266. Chan LS, Vanderlugt CJ, Hashimoto T, Nishikawa T, Zones JJ, Black MM, Wojnarowask F, Stevens SR, Chen M, Failey JA, Miller SD, Gordon KB (1998) Epitope spreading: Lessons from autoimmune skin diseases. J Invest Dermatol 110: 103–109Google Scholar
  267. Chen D, Welsh EA, Woodley DT, Wynn KC, Briggaman RA, Kim YH (1992): Passive transfer of autoantibodies of epidermolysis bullosa acquisita antibody into xenotransduced SCID mice with human graft. J Invest Dermatol 98: 589Google Scholar
  268. Chen M, Marinkovich MP, Veis A, O’Toole EA, Rao CN, Cai XY, Woodley DT (1997a) Interactions of the amino-terminal noncollagenous (NCI.) domain of type VII collagen with extracellular matrix components: a potential role in epidermal-dermal adherence in human skin. J Biol Chem 272: 14516–14522PubMedCrossRefGoogle Scholar
  269. Chen M, Chan LS, Cai X, O’Toole EA, Sample JC, Woodley DT (1997b) Development of an FT.ISA for rapid detection of anti-type VTT collagen autoantibodies in epidermolysis bullosa acquisita. J Invest Dermatol 108: 68–72PubMedCrossRefGoogle Scholar
  270. Chen M, O’Toole EA, Sanghavi J, Mahmud N, Kelleher D, and Woodley DT (1997c) Type VII collagen exists in human intestine and serves as an antigenic target in patients with inflammatory bowel disease. J Invest Dermatol 108: 542Google Scholar
  271. Chen M, Marinkovich MP, Jones JC, O’Toole E, Li YY, Woodley DT (1999) NC1 domain of type VII collagen binds to the beta3 chain of laminin 5 via a unique subdomain within the fibronectin-like repeats. J Invest Dermatol 112: 177–183PubMedCrossRefGoogle Scholar
  272. Chen M, Tahk SH, Costa FK, Kasahara N, Woodley DT (2000a) Recombinant expression of full-length type VII collagen alpha chain: structural and functional characterization and implication for gene therapy. J Invest Dermatol 114: 756Google Scholar
  273. Chen M, Wang J, Tahk SH and Woodley DT (2000b) Noncollagenous (NC2) domain of type VII collagen mediates the antiparallel-dimer formation of type VII collagen and constitutes a new antigenic epitope for EBA and BSLE autoantibodies. J Invest Dermatol 114: 766Google Scholar
  274. Cho HJ, Lee IJ, Kim SC (1998) Complement fixing abilities and IgG subclasses of autoantibodies in epidermolysis bullosa acquisita. Yonsei Medical Journal 39: 339–344PubMedGoogle Scholar
  275. Choi GS, Lee ES, Kim SC, Lee S (1998) Epidermolysis bullosa aquisita localized to the face. J Dermatol 25: 19–22PubMedGoogle Scholar
  276. Christiano AM, Greenspan DS, Lee S, and Uitto, J (1994) Cloning of human type VII collagen: complete primary sequence of the alpha 1(VII) chain and identification of intragenic polymorphisms. J Biol Chem 269: 20256–20262PubMedGoogle Scholar
  277. Connolly SM, Sander HM (1987) Treatment of epidermolysis bullosa acquisita with cyclosporin. J Am Acad Dermatol 16: 890PubMedCrossRefGoogle Scholar
  278. Crow LL, Finkle JP, Gammon WR, Woodley DT (1988) Cleaning of epidermolysis bullosa acquisita on cyclosporin A. J Am Acad Dermatol 19: 937–942PubMedCrossRefGoogle Scholar
  279. Cunningham BB, Kirchmann TT, Woodley DT (1996) Colchicine for epidermolysis bullosa ( EBA ). J Am Acad Dermatol 34: 781–784Google Scholar
  280. Dahl MG (1979) Epidermolysis bullosa acquisita–a sign of cicatricial pemphigoid? Br J Dermatol 101: 475–483PubMedCrossRefGoogle Scholar
  281. De Jong MCJM, Bruins S, Heeres K, Jonkman MF, Nieboer C, Boorsma DM, Pas HH, van der Meer JB (1996) Bullous pemphigoid and epidermolysis bullosa acquisita: Differentiation by fluorescence overlay antigen mapping. Arch Dermatol 132: 151–157Google Scholar
  282. Domloge-Hultsch N, Anhalt GJ, Gammon WR, Lazarova Z, Briggaman R, Welch M, Jabs DA, Huff C, Yancey KB (1994) Antiepiligrin cicatricial pemphigoid: A subepithelial bullous disorder. Arch Dermatol 130: 1521–1529Google Scholar
  283. Edwards S, Wakelin SH, Wojnarowska F, Marsden RA, Kirtschig G, Bhogal B, Black MM (1998) Bullous pemphigoid and epidermolysis bullosa acquisita: presentation, prognosis, and immunopathology in 11 children. Pediatr Dermatol 15: 184–190PubMedCrossRefGoogle Scholar
  284. Elliott GT (1895) Two cases of epidermolysis bullosa. J Cutan Genitourin Dis 13: 10 Epstein JH, Tuffanelli DL, Epstein WL (1973) Cutaneous changes in the porphyrias. A microscopic study. Arch Dermatol 107: 689–698Google Scholar
  285. Feliciani C, Di Muzio M, Mohammad Pour S, Allegretti T, Amerio P, Toto P, Coscione G, Proietto G, Amerio P (1998) ‘Suction split’ as a routine method to differentiate epidermolysis bullosa acquisita from bullous pemphigoid. J Eur Acad Dermatol Venereol 10: 243–247Google Scholar
  286. Fine JD, Tyring S, Gammon WR (1989) The presence of intra-lamina lucida blister formation in epidermolysis bullosa acquisita: Possible role of leukocytes. J Invest Dermatol 92: 27Google Scholar
  287. Furue M, Iwata M, Yoon H-I, Kubota Y, Ohto H, Kawashima M, Tsuchida T, Oohara K, Tamaki K, Kukita A (1986) Epidermolysis bullosa acquisita: clinical response to plasma exchange therapy and circulating anti-BMZ antibody titer. J Am Acad Dermatol 14: 873–878PubMedCrossRefGoogle Scholar
  288. Gammon WR, Briggaman RA, Wheeler CE Jr (1982) Epidermolysis bullosa acquisita presenting as an inflammatory bullous disease. J Am Acad Dermatol 7: 382–387PubMedCrossRefGoogle Scholar
  289. Gammon WR, Briggaman RA, Inman AO, Queen LL, Wheeler CE (1984a) Differentiating anti-lamina lucida and antisublamina densa anti-BMZ antibodies by indirect immune ofluorescence on 1.0 M sodium chloride-separated skin. J Invest Dermatol 82: 139–144PubMedCrossRefGoogle Scholar
  290. Gammon WR, Briggaman RA, Woodley DT, Heald PW. Wheeler CE Jr (1984b) Epidermolysis bullosa acquisita–a pemphigoid like disease. J Am Acad Dermatol 11: 820–832PubMedCrossRefGoogle Scholar
  291. Gammon WR, Woodley DT, Dole KC, Briggaman RA (1985) Evidence that basement membrane zone antibodies in bullous eruption of systemic lupus erythematosus recognize epidermolysis bullosa acquisita autoantigens. J Invest Dermatol 84: 472–476PubMedCrossRefGoogle Scholar
  292. Gammon WR (1988a) Epidermolysis bullosa acquisita. Semin Dermatol 7: 218–224PubMedGoogle Scholar
  293. Gammon WR, Heise ER, Burke WA, Fine JD, Woodley DT, Briggaman RA (1988b) Increased frequency of HLA-DR2 in patients with autoantibodies to epidermolysis bullosa acquisita antigen: Evidence that the expression of autoimmunity to type VII collagen is HLA class II allele associated. J Invest Dermatol 91: 228–232Google Scholar
  294. Gammon WR, Kowalewski C, Chorzelski TP, Kumar V, Briggaman RA, Beutner EH (1990) Direct immunofluorescence studies of sodium chloride-separated skin in the differential diagnosis of bullous pemphigoid and epidermolysis bullosa acquisita. J Am Acad Dermatol 22: 664–670PubMedCrossRefGoogle Scholar
  295. Gammon WR, Briggaman RA (1993) Epidermolysis bullosa acquisita and bullous systemic lupus erythematosus: disease of autoimmunity to type VII collagen. Dermatol Clin 11: 535–547PubMedCrossRefGoogle Scholar
  296. Gammon WR, Murrell DF, Jenson MW, Padilla KM, Prisayanh PS, Jones DA, Briggaman RA, and Hunt SW III (1993) Autoantibodies to type VII collagen recognize epitopes in a fibronectin-like region of the noncollagenous (NC1) domain. J Invest Dermatol 100: 618–622PubMedCrossRefGoogle Scholar
  297. Ghohestani RF, Nicolas JF, Roussele P, Claudy AL (1997) Diagnostic value of indirect immunofluorescence on sodium chloride-split skin in differential diagnosis of subepidermal autoimmune bullous dermatoses. Arch Dermatol 133: 1102–1107PubMedCrossRefGoogle Scholar
  298. Gordon KB, Chan LS, Woodley DT (1997) Treatment of refractory epidermolysis bullosa acquisita with extracorporeal photochemotherapy. Br J Dermatol 136: 415–420PubMedCrossRefGoogle Scholar
  299. Harman KE, Whittam LR, Wakelin SH, Black MM (1998) Severe, refractory epidermolysis bullosa acquisita complicated by an oesophageal stricture responding to intravenous immune globulin. Br J Dermatol 139: 1126–1127PubMedCrossRefGoogle Scholar
  300. Hashimoto T, Ishiko A, Shimizu H, Tanaka T, Dodd HJ, Bhogal BS, Black MM, Nishikawa T (1996) A case of linear IgA bullous dermatosis with IgA anti-type VII collagen autoantibodies. Br J Dermatol 134: 336–339PubMedCrossRefGoogle Scholar
  301. Hoang-Xuan T, Robin H, Heller M, Caux F, Prost C (1997) Epidermolysis bullosa acquisita diagnosed by direct immunoelectron microscopy of the conjunctiva. Ophthalmology 104: 1414–1420PubMedGoogle Scholar
  302. Jappe U, Zillikens D, Bonnekoh B, Gollnick H (2000) Epidermolysis bullosa acquisita with ultraviolet radiation sensitivity. Br J Dermatol 142: 517–520PubMedCrossRefGoogle Scholar
  303. Joly P, Ruto F, Thomine E, Delpech A, Balguerie X, Tron F, Lauret P (1993) Brunsting-Perry Cicatricial Bullous Pemphigoid: a clinical variant of localized acquired epidermolysis bullosa? J Am Acad Dermatol 28: 89–92PubMedCrossRefGoogle Scholar
  304. Jones DA, Hunt SW III, Prisayanh PS, Briggaman RA, Gammon WR (1995) Immunodominant autoepitopes of type VII collagen are short, paired peptide sequences within the fibronectin type III homology region of the noncollagenous (NC1) domain. J Invest Dermatol 104: 231–235PubMedCrossRefGoogle Scholar
  305. Jonkman MF, Schuur J, Dijk F, Heeres K, de Jong MC, van der Meer JB, Yancey KB, Pas HH (2000) Inflammatory variant of epidermolysis bullosa acquisita with IgG autoantibodies against type VII collagen and laminin a3 Arch Dermatol 136: 227–231Google Scholar
  306. KazamaT, Yamamoto Y, Hashimoto T, Komai A, Ito M (1998) Application of confocal laser scanning microscopy to differential diagnosis of bullous pemphigoid and epidermolysis bullosa acquisita. Br J Dermatol 138: 593–601CrossRefGoogle Scholar
  307. Kofler H, Wambacher-Gasser B, Topar G, Weinlich G, Schuler G, Hintner H, Romani N, Fritsch P (1997) Intravenous immunoglobulin treatment in therapy–resistant epidermolysis bullosa acquisita. J Am Acad Dermatol 36: 331–335PubMedCrossRefGoogle Scholar
  308. Kurzhals G, Stolz W, Meurer M, Kunze J, Braun-Falco O, Krieg T (1991) Acquired epidermolysis bullosa with the clinical feature of Brunsting-Perry cicatricial bullous pemphigoid. Arch Dermatol 127: 391–395PubMedCrossRefGoogle Scholar
  309. Kushniruk W (1973) The immunopathology of epidermolysis bullosa acquisita. Can Med Assoc J 108: 1143–1146PubMedGoogle Scholar
  310. Lapiere JC, Woodley DT, Parente MG, Iwasaki T, Wynn KC, Christiano AM, Uitto J (1993) Epitope mapping of type VII collagen: identification of discrete peptide sequences recognized by sera from patients with acquired epidermolysis bullosa. J Clin Invest 92: 1831–1839PubMedCrossRefGoogle Scholar
  311. Leplere JC, Chen JD, Iwasaki T, Hu L, Uitto J, Woodley DI (1994) ‘type Vil collagen specifically binds fibronectin via a unique subdomain within the collagenous triple helix. J Invest Dermatol 103: 637–641Google Scholar
  312. Lee CW (1998) Prevalences of subacute cutaneous lupus erythematosus and epidermolysis bullosa acquisita among Korean/oriental papulations. Dermatology 197: 187PubMedCrossRefGoogle Scholar
  313. Lee CW (2000) Serum IgA autoantibodies in patients with epidermolysis bullosa acquisita: A high frequency of detection. Dermatology 200: 83–84PubMedCrossRefGoogle Scholar
  314. Lever WF, Schaumburg-Lever G (1990) Congenital disease (genodermatoses). In Histopathology of the skin, edited by WF Lever, G Schaumburg-Lever. Philadephia, Lippincott, p 78Google Scholar
  315. Lohi J, Leivo I, Tani T, Kiviluoto T, Kivilaakso E, Burgeson RE, Virtanen I (1996) Laminins, tenascin and type VII collagen in colorrectal mucosa. Histochem J 28: 431–440PubMedCrossRefGoogle Scholar
  316. Mascaro JM Jr, Zillikens D, Giudice GJ, Caux F, Fleming MG, Katz HM, Diaz LA (2000) A subepidermal bullous eruption associated with IgG autoantibodies to a 200 kd dermal antigen: The first case report from the United States. J Am Acad Dermatol 242: 309–315Google Scholar
  317. Megahed M, Scharfetter-Kochanek K (1994) Epidermolysis bullosa acquisita-successful treatment with colchicine. Arch Dermatol Res 286: 35–46PubMedCrossRefGoogle Scholar
  318. Miller JK, Stricklin GP, Fine JD, King LE, Arzubiaga MC, Ellis DL (1995) Remission of svere epidermolysis bullosa acquisita induced by extracoporeal photochemotherapy. Br J Dermatol 133: 467–471PubMedCrossRefGoogle Scholar
  319. Nieboer C, Boorsma DM, Woerdeman MJ, Kalsbeek GL (1980) Epidermolysis bullosa acquisita: immunofluorescence, electron microscopic and immunoelectron microscopic studies in four patients. Br J Dermatol 102: 383–392PubMedCrossRefGoogle Scholar
  320. Paller AS, Queen LL, Woodley DT, Lane AT, Gammon WR, Briggaman RA (1986) Organ specific, phylogenic and ontogenetic distribution of the epidermolysis bullosa acquisita antigen. J Invest Dermatol 86: 376–379PubMedCrossRefGoogle Scholar
  321. Park SB, Cho KH, Youn JL, Hwang DH, Kim SC, Chung JH (1997) Epidermolysis bullosa aquisita in childhood–a case mimicking chronic bullous dermatosis of childhood. Clin Exp Dermatol 22: 220–222PubMedCrossRefGoogle Scholar
  322. Ray TL, Levine JB, Weiss W, Ward PA (1982) Epidermolysis bullosa acquisita and inflammatory bowel disease. J Am Acad Dermatol 6: 242–252PubMedCrossRefGoogle Scholar
  323. Richter BJ, McNutt NS (1979) The spectrum of epidermolysis bullosa acquisita. Arch Dermatol 115: 1325–1328PubMedCrossRefGoogle Scholar
  324. Roenigk HH, Ryan JG, Bergfeld WF (1971) Epidermolysis bullosa acquisita: Report of three cases and review of all published cases. Arch Dermatol 103: 1–10Google Scholar
  325. Rook AH, Jegasothy BV, Heald P, Nahass GT, Ditre C, Witmer WK, Lazarus GS, Edelson RL (1990) Extracoporeal photochemotherapy for drug-resistant pemphigus vulgaris. Ann Intern Med 112: 303–305PubMedGoogle Scholar
  326. Rusenko KW, Gammon WR, and Briggaman RA (1989) Type VII collagen is the antigen recognized by IgA anti-sub lamina densa autoantibodies. J Invest Dermatol 92: 510 AbstractGoogle Scholar
  327. Sakai LY, Keene DR, Morris NP, Burgeson RE (1986) Type VII collagen is a major structural component of anchoring fibrils. J Cell Biol 103: 1577–1586PubMedCrossRefGoogle Scholar
  328. Schattenkirchner S, Eming S, Hunzelmann N, Krieg T, Smola H (1999) Treatment of epidermolysis bullosa acquisita with mycophenolate mofetil and autologous keratinocyte grafting. Br J Dermatol 141: 932–933PubMedCrossRefGoogle Scholar
  329. Schaumburg-Lever G, Rule A, Schmidt-Ullrich B, Lever WF (1975) Ultrastructural localization of in vivo bound immunoglobulins in bullous pemphigoid–A prelimnary report. J Invest Dermatol 64: 47–49PubMedCrossRefGoogle Scholar
  330. Stewart MI, Woodley DT, Briggaman RA (1991) Acquired epidermolysis bullosa and associated symptomatic esophageal webs. Arch Dermatol 127: 373–377PubMedCrossRefGoogle Scholar
  331. Tanaka H, Ishida-Yamamoto A, Hashimoto T (1997) A novel variant of acquired epidermolysis bullosa with autoantibodies against the central triple-helical domain of type VII collagen. Lab Invest 77: 623–632PubMedGoogle Scholar
  332. Taniuchi K, Inaoki M, Nishimura Y, Mori T, Takehara K (1997) Nonscarring inflammatory epidermolysis bullosa acquisita with esophageal involvement and linear IgG deposits. J Am Acad Dermatol 36: 320–322PubMedCrossRefGoogle Scholar
  333. Tokuda Y, Amagai M, Yaoita H, Kawachi S, Ito T, Matsuyama I, Tsuchiya S, Saida T (1998) A case of inflammatory variant of epidermolysis bullosa acquisita: Chronic bullous dermatosis associated with non scarring mucosal blisters and circulating IgG anti-type-VII-collagen antibody. Dermatology 197: 58–61Google Scholar
  334. Uitto J, Christiano AM (1994) Molecular basis for the dystrophic forms of epidermolysis bullosa: mutations in the type VII collagen gene. Arch Dermatol Res 287: 16–22PubMedCrossRefGoogle Scholar
  335. Vodegel RM, Kiss M, De Jong MCJM, Pas HH, Altmayer A, Molnar K, Husz S, Van Der Meer JB, Jonkman MF (1998) The use of skin substrate deficient in basement membrane molecules for the diagnosis of subepidermal autoimmune bullous disease. Eur J Dermatol 8: 83–85PubMedGoogle Scholar
  336. Wieme N, Lambert J, Moerman M, Geerts ML, Temmerman L, Naeyaert JM (1999) Epidermolysis bullosa acquisita with combined features of bullous pemphigoid and cicatricial pemphigoid. Dermatology 198: 310–313PubMedCrossRefGoogle Scholar
  337. Woodley DT, Sauder D, Talley MJ, Silver M, Grotendorst G, Qwarnstrom E (1983) Localization of basement membrane components after DEJ separation. J Invest Dermatol 81: 149–153PubMedCrossRefGoogle Scholar
  338. Woodley DT, Briggaman RA, O’Keefe EJ, Inman AO, Queen LL, Gammon WR (1984) Identification of the skin basement-membrane autoantigen in epidermolysis bullosa acquisita. N Engl J Med 310: 1007–1015PubMedCrossRefGoogle Scholar
  339. Woodley DT, O’Keefe EJ, Reese MJ, Mechanic GL, Briggaman RA, Gammon WR (1986) Epidermolysis bullosa acquisita antigen, a new major component of cutaneous basement membrane, is a glycoprotein with collagenous domains. J Invest Dermatol 86: 668–672PubMedCrossRefGoogle Scholar
  340. Woodley DT (1988) Epidermolysis bullosa acquisita. Prog Dermatol 22: 1Google Scholar
  341. Woodley DT, Burgeson RE, Lunstrum G, Bruckner-Tuderman L, Reese MJ, Briggaman RA (1988) The epidermolysis bullosa acquisita antigen is the globular carboxyl terminus of type VII procollagen. J Clin Invest 81: 683–687PubMedCrossRefGoogle Scholar
  342. Woodley DT, Gammon WR, Briggaman RA (1998) Epidermolysis bullosa acquisita. In: Fitzpatrick TB, Eisen AZ, Wolff K, Freedberg IM, Austen KF, editors. Dermatology in general medicine. 4th ed. Vols. I-II. McGraw-Hill, New York, 702–709Google Scholar
  343. Yancey KB. Cicatricial pemphigoid. In: Fitzpatrick TB, Eisen AZ, Wolff K, Freedberg IM, Austen KF (1998) Dermatology in general medicine. 4th ed. Vols. I–II. McGraw-Hill, New York, Inc., pp 674–679Google Scholar
  344. Yaoita H, Briggaman A, Lawley TJ, Provost TT, Katz SI (1981) Epidermolysis bullosa acquisita: Ultrastructural and immunological studies. J Invest Dermatol 76: 288–292Google Scholar
  345. Zillikens D, Weyer S, Roth A, Hashimoto T, Brocker EB (1995) Incidence of autoimmune subepidermal blistering dermatoses in a region of central Germany. Arch Dermatol 131: 957–958PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 2001

Authors and Affiliations

  • Michael Hertl
  • Emmanuel Laffitte
  • Luca Borradori
  • Christian Rose
  • Detlef Zillikens
  • Mei Chen
  • Dafna Hallel-Halevy
  • Celina Nadelman
  • David T. Woodley

There are no affiliations available

Personalised recommendations